diaDexus, Inc., based in South San Francisco, California, is focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease.
The PLAC Test for Lp-PLA2, diaDexus' flagship product, addresses key unmet medical need, providing actionable information. The PLAC Test for Lp-PLA2 is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States.
View all » Recent Releases
Aug 18, 2014
diaDexus, Inc. Secures $15 Million Debt Financing